TNFRSF17 and Miyoshi myopathy: At present, anti-BCMA CAR-T cell therapy has been demonstrated to be effective in R/R MM and achieved unprecedented responses (7, 8, 67–69), and two anti-BCMA CAR-T cell products, idecabtagene vicleucel and ciltacabtagene autoleucel, have been approved by the FDA for the treatment of R/R MM (7, 70).